Akari Therapeutics, Plc
Akari Therapeutics, Plc (AKTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
aktx · stock forecast · 8 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1200
Consensus
$1200
+7669.5% upside
Low
$1200
Median: $1200 · Last Close: $15.45
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $15.45 | ↑ 0.00% |
1-day model range: $14.98–$15.91. Peak: $15.91 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AKTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-08 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2026-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-12-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-11-01 | Alliance Global Partners | Maintains | Buy→Buy |
| 2020-03-13 | B. Riley FBR | Maintains | Buy→Buy |
| 2020-03-13 | B. Riley Securities | Maintains | Buy→Buy |
| 2020-03-12 | B. Riley Securities | Maintains | Buy→Buy |
| 2018-05-05 | B. Riley FBR | Maintains | Neutral→Neutral |
| 2018-03-29 | Canaccord Genuity | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Akari Therapeutics, Plc (AKTX) stock. Of the recent 17 rating actions, 2 were upgrades and 3 were downgrades. 8 analysts currently cover AKTX.
Analyst Recommendation Trends
AKTX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$10M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$-5.77
EPS Next Year
$-4.68
↓ 18.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast AKTX EPS of $-5.77 for the current fiscal year, based on estimates from 2 analysts. The AKTX revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AKTX stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AKTX price target is $1200.00 (+7669.5% upside), with an analyst consensus of Buy.
The AKTX short-term stock prediction for tomorrow is $15.45 (+0.00%).
Akari Therapeutics, Plc trades on NASDAQ under the ticker AKTX. The AKTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
AKTX forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month AKTX price target is $1200.00, with a high forecast of $1200.00 and a low of $1200.00. The median price target is shown in the chart above when available. This implies +7669.5% potential upside from the current price of $15.45.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.